Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology makes it possible to use the cells own machinery to reverse mutations that cause a genetic disease. Read the interview.
ProQR management will host an investor conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the recently announced partnership with Lilly.
Axiomer® platform applicability and potential in therapeutically relevant models for targeted RNA editing presented at TIDES EU 2018 by Antti Aalto - ProQR Therapeutics
… of the communities we serve. Our proprietary Axiomer™ RNA editing technology platform enables the editing of … in RNA using the cells own editing machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine Deaminase … currently untreatable diseases. By harnessing the power of RNA editing, we aim to create a world where genetics inform …
… of the communities we serve. Our proprietary Axiomer™ RNA editing technology platform enables the editing of … in RNA using the cells own editing machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine Deaminase … currently untreatable diseases. By harnessing the power of RNA editing, we aim to create a world where genetics inform …
Chardan’s 9th Annual Genetic Medicines Conference – October 21, 2025
Company management will participate in an RNA Editing panel at 1:00 p.m. ET and will conduct 1x1 investor meetings in conjunction with the conference.
ProQR will host a virtual Analyst and Investor Event on Wednesday, December 11, 2024 from 10:00 am until approximately 12:30 pm EST, including an Analyst Q&A session with members of the ProQR Management Team.
ProQR has announced the completion of an in-depth strategic review designed to deliver on our commitment to advance RNA therapies for diseases with high unmet need. We are also sharing additional analyses of the sepofarsen Illuminate trial.
